| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Dermata Therapeutics Inc. | Xyngari(TM) (DMT310) - (STAR-1) | Moderate-to-severe acne | Phase 3 | Data Released | Topical | #N/A |
| Dermata Therapeutics Inc. | Xyngari(TM) (DMT310) | Rosacea | Phase 2 | Topical | N/A | |
| Dermata Therapeutics Inc. | DMT410 | Axillary Hyperhidrosis | Phase 2a | Trial Planned | Intralesional | N/A |
| DiaMedica Therapeutics Inc. | DM199 (rinvecalinase alfa) | Preeclampsia (PE) | Phase 2 | Trial Planned | Intravenous | Women's Health |
| DiaMedica Therapeutics Inc. | Rinvecalinase Alfa (DM199) - (ReMEDy2) | Acute ischaemic stroke (AIS) | Phase 2/3 | Ongoing | Intravenous | Neurology |
| DiaMedica Therapeutics Inc. | DM199 - (REDUX) | Chronic Kidney Disease | Phase 2 | Trial Completed | Intravenous | N/A |
| Dianthus Therapeutics Inc Com | MGTA-145 and plerixafor | Sickle Cell Disease | Phase 2 | Trial Discontinued | Subcutaneous injection | Hematology |
| Dianthus Therapeutics Inc. | Claseprubart - (MaGic) | Generalized Myasthenia Gravis (gMG) | Phase 2 | Data Released | Oral | Neurology |